239 related articles for article (PubMed ID: 12747285)
1. Molecular differences in anticytokine therapies.
Calabrese LH
Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
[TBL] [Abstract][Full Text] [Related]
2. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
3. Biological response modifiers in the management of rheumatoid arthritis.
Louie SG; Park B; Yoon H
Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
[TBL] [Abstract][Full Text] [Related]
4. [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].
Sautner J; Leeb BF
Wien Med Wochenschr; 2003; 153(13-14):304-8. PubMed ID: 12924105
[TBL] [Abstract][Full Text] [Related]
5. [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].
Botsios C; Ostuni P; Sfriso P; Furlan A; Fiocco U; Sgarabotto D; Todesco S
Reumatismo; 2003; 55(4):224-35. PubMed ID: 14872221
[TBL] [Abstract][Full Text] [Related]
6. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
8. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
9. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
Schnabel A; Gross WL
Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
[No Abstract] [Full Text] [Related]
10. [Anti-cytokine therapy for connective tissue disease].
Hayashi T; Goto D; Sumida T
Nihon Rinsho; 2005 May; 63 Suppl 5():233-9. PubMed ID: 15954355
[No Abstract] [Full Text] [Related]
11. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
Fleishmann RM
Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
[TBL] [Abstract][Full Text] [Related]
12. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
13. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R; Bansback N; Brennan A
Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
16. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
18. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
19. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
